NCT03435250: Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: CDK, MTAP
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have homozygous loss of CDKN2A or MTAP in tumor tissue
Exclusions: Metastasis to the CNS that is symptomatic and/or requires therapy

Comments are closed.

Up ↑